Literature DB >> 2450258

Postsynaptic alpha 1- and alpha 2-adrenergic mechanisms in coronary vasoconstriction.

D G Chen1, X Z Dai, B G Zimmerman, R J Bache.   

Abstract

This study examined the relative importance of postsynaptic alpha 1- and alpha 2-adrenoceptors in mediating coronary vasoconstriction in open chest dogs in which the left circumflex coronary artery was cannulated and perfused at a constant rate. The cervical vagus nerves and central connections of the stellate ganglia were transected, and beta-adrenergic blockade was produced with propranolol. Coronary vasoconstriction occurred in response to intraarterial administration of both the alpha 1-agonist phenylephrine and the alpha 2-agonist BHT 933. The response to phenylephrine was partially blocked with prazosin and nearly completely eliminated by yohimbine. The response to BHT 933 was resistant to prazosin, but almost completely blocked by yohimbine. Coronary vasoconstriction produced by norepinephrine was resistant to prazosin, but was blunted by alpha 2-adrenergic blockade with yohimbine or idazoxan. Prazosin produced some blunting of coronary vasoconstriction in response to small doses of epinephrine, while yohimbine markedly attenuated epinephrine-induced vasoconstriction at all doses used. Measurements of regional myocardial blood flow with radioactive microspheres demonstrated no transmural redistribution of perfusion during vasoconstriction produced by either alpha 1- or alpha 2 stimulation. Thus, although stimulation of both alpha 1- and alpha 2-adrenoceptors is capable of causing coronary vasoconstriction, vasoconstriction in response to norepinephrine and epinephrine is mediated principally by postsynaptic alpha 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450258     DOI: 10.1097/00005344-198801000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

3.  Effect of dexmedetomidine, an alpha2-adrenoceptor agonist, on human pupillary reflexes during general anaesthesia.

Authors:  M D Larson; P O Talke
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

4.  Intravenous dexmedetomidine for treatment of intraoperative penile erection.

Authors:  Gulen Guler; Mustafa Sofikerim; Fatih Ugur; Recep Aksu; Adem Boyaci
Journal:  Int Urol Nephrol       Date:  2011-06-24       Impact factor: 2.370

Review 5.  Alpha-adrenergic control of coronary circulation in man.

Authors:  C Indolfi; A Rapacciuolo; M Condorelli; M Chiariello
Journal:  Basic Res Cardiol       Date:  1994 Sep-Oct       Impact factor: 17.165

6.  Intravenous phentolamine abolishes coronary vasoconstriction in response to mild central hypovolemia.

Authors:  Zhaohui Gao; Matthew D Muller; Lawrence I Sinoway; Urs A Leuenberger
Journal:  J Appl Physiol (1985)       Date:  2013-12-05

Review 7.  Neuronal control of coronary blood flow.

Authors:  D Baumgart; G Heusch
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

8.  Alpha 1-adrenergic blockade reduces exercise-induced regional myocardial ischemia in dogs.

Authors:  B D Guth; T Miura; E Thaulow; G Heusch; J Ross
Journal:  Basic Res Cardiol       Date:  1993 May-Jun       Impact factor: 17.165

9.  Felodipine prevents the poststenotic myocardial ischemia induced by alpha 2-adrenergic coronary constriction.

Authors:  T Ehring; G Heusch
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.